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Anthracyclines are very effective chemotherapeutic agents; however, their use is
hampered by the treatment-induced cardiotoxicity. Genetic variants that help define
patient’s sensitivity to anthracyclines will greatly improve the design of optimal
chemotherapeutic regimens. However, identification of such variants is hampered by
the lack of analytical approaches that address the complex, multi-genic character of
anthracycline induced cardiotoxicity (AIC). Here, using a multi-SNP based approach,
we examined 60 genes coding for proteins involved in drug metabolism and efflux
and identified the P450 oxidoreductase (POR) gene to be most strongly associated
with daunorubicin induced cardiotoxicity in a population of acute myeloid leukemia
(AML) patients (FDR adjusted p-value of 0.15). In this sample of cancer patients,
variation in the POR gene is estimated to account for some 11.6% of the variability
in the drop of left ventricular ejection fraction (LVEF) after daunorubicin treatment,
compared to the estimated 13.2% accounted for by the cumulative dose and ethnicity.
In post-hoc analysis, this association was driven by 3 SNPs—the rs2868177, rs13240755,
and rs4732513—through their linear interaction with cumulative daunorubicin dose.
The unadjusted odds ratios (ORs) and confidence intervals (CIs) for rs2868177 and
rs13240755 were estimated to be 1.89 (95% CI: 0.7435–4.819; p = 0.1756) and 3.18 (95%
CI: 1.223–8.27; p = 0.01376), respectively. Although the contribution of POR variants is
expected to be overestimated due to the multiple testing performed in this small pilot
study, given that cumulative anthracycline dose is virtually the only factor used clinically to
predict the risk of cardiotoxicity, the contribution that genetic analyses of POR can make
to the assessment of this risk is worthy of follow up in future investigations.
Keywords: anthracycline induced cardiotoxicity, daunorubicin, acute myeloid leukemia, P450 oxidoreductase
variants, complex trait, global test, adverse drug reactions
INTRODUCTION
Anthracyclines are very effective chemotherapeutic agents used
in the treatment of a wide variety of leukemias, lymphomas,
and solid tumors. Due to their high efficacy and broad-spectrum
application, these agents are being used despite the associated side
effects. The most adverse side effect of anthracycline therapy is
cardiotoxicity, which often leads to chronic cardiomyopathy and
in some cases congestive heart failure and death (Sawyer et al.,
2010). In addition to limiting the dose of the drug adminis-
tered, several other strategies, including liposomal encapsulation,
modification of anthracycline structure, and concurrent admin-
istration of iron chelators, have been used as attempts to lessen
the cardiotoxic effect of anthracycline treatment (Sawyer et al.,
2010). Despite these efforts, chronic cardiomyopathy remains as a
life-long threat with the risk for chronic heart failure ranging from
3 to 26% depending on the dose of the drug (Yeh and Bickford,
2009).
The proposed risk factors for anthracycline induced cardiotox-
icity (AIC) include cumulative dose, age, gender, pre-existent
medical conditions, and combination therapy (Menna et al.,
2012). Among these risk factors, the strongest is the cumula-
tive dose of the drug. Consequently, physicians and regulators
have set limits on the maximum anthracycline dose that can
be used. However, the variability in sensitivity to anthracyclines
is quite broad and some patients experience cardiotoxicity with
doses as low as 200mg/m2, while others tolerate doses as high
as 1000mg/m2 (Yeh and Bickford, 2009). These observations
suggest that there is no truly “safe” anthracycline dose and
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bio-markers are needed to identify patients vulnerable to AIC, as
well as those that can tolerate much higher doses of the drugs with
little risk, and thus could benefit from more aggressive treatment
(Estey, 2012; Menna et al., 2012).
The range of variability among patients in their sensitivity
to anthracyclines cannot be fully explained by the known risk
factors or pharmacokinetic parameters, and suggests there is an
indispensible genetic component (Duan et al., 2007). Genetic
contribution to the variability in sensitivity is further supported
by the relatively high heritability of anthracycline cytotoxicity
(h2 = 0.18–0.63) (Duan et al., 2007; Peters et al., 2011). A num-
ber of predisposing genetic variants have been reported; however,
these do not explain all of the variability in risk (Wojnowski et al.,
2005; Blanco et al., 2008, 2012; Rajic et al., 2009; Visscher et al.,
2012). The limited success of genetic studies searching for variants
that would explain all of the observed variability in AIC suggests
that AIC is a complex phenotype with many genes, environ-
mental factors, and gene-environment interactions contributing
to its development (Duan et al., 2007). For such complex traits
many genes (even hundreds) contribute to the final phenotype
and variants at each of the loci will generally have a modest
effect. Therefore, they are difficult to identify, and will often be
missed by the standard single-variant based association tests (De
Bakker et al., 2005; Kraft and Hunter, 2009; De Los Campos et al.,
2010; Yang et al., 2010; Stringer et al., 2011). Moreover, single-
variant based association tests ignore the possibility of synergistic
and gene-environment interactions, which often results in miss-
ing potentially important loci (Ober and Vercelli, 2011; Wheeler
et al., 2012). Increasing the size of the study sample will increase
the power to detect variants that have modest effects. However,
even a large (e.g., 10,000 subjects) study sample will have low
power to detect any specific marker with the least stringent signif-
icance threshold (p = 10−7) in a genome-wide association study
of thousands of SNPs (Kraft and Hunter, 2009). Therefore, in
realistically sized study samples, the search for genetic variants of
complex, polygenic traits requires a multi-variant based approach
that allows for potential gene-environment interactions to iden-
tify genetic contributors of small or modest effect (De Bakker
et al., 2005; Ober and Vercelli, 2011; Wheeler et al., 2012).
The exact causes of AIC are unclear; however, data accu-
mulated to date indicates that anthracycline metabolism, either
through generation of free radicals or toxic metabolites, or a
combination of both, is a significant contributor to the drugs’ car-
diotoxicity (Sawyer et al., 2010; Menna et al., 2012). Therefore, we
selected 60 genes coding for proteins involved in drugmetabolism
and efflux as candidates for a pilot project focused on identi-
fying candidate markers of AIC in a sample of acute myeloid
leukemia (AML) patients undergoing daunorubicin (DAUN)
based treatment. Using a multi-variant based approach that
allows for potential gene-anthracycline dose interactions, we
identify genetic variants in the POR gene as potential markers of
AIC among AML patients undergoing DAUN treatment.
MATERIALS AND METHODS
PATIENTS AND CLINICAL OUTCOME DEFINITION
Peripheral blood samples were obtained from 286 AML patients
after informed consent and with approval from the Clinical
Research Ethics Board of the University of British Columbia. The
patient samples were obtained over an 8–10 years period and
the samples and patient data were examined retrospectively. All
patients received DAUN or mitoxantrone (MITOX) in combina-
tion with cytarabine for initial remission induction and subse-
quent consolidation therapy. For each patient cardiac function
was monitored by left ventricular ejection fraction (LVEF) mea-
surements determined with radionuclide ventriculogram (RVG)
scans and/or echocardiograms. This patient population has been
described in more detail elsewhere (Kim et al., 2012).
PATIENT SELECTION
The aim of this study was to identify genetic variants that render
some patients vulnerable to the cardiotoxic side effect of anthra-
cycline treatment. Since objective measurement of cardiotoxicity
due to treatment (and not other causes) can only be done if cardiac
function is assessed before and after treatment, only patients that
had their LVEF measurements done before and after (less than
a year after last dose of anthracycline) anthracycline treatment
were used in subsequent statistical analyses (114 patients).
Percentage drop in LVEF was used as a measure of decrease in
cardiac function after treatment. LVEF is a measure commonly
used to monitor cardiac function in patients undergoing anthra-
cycline treatment and allows for analysis of cardiotoxicity as a
quantitative trait (Ewer and Ewer, 2009). A genetic statistical anal-
ysis of such traits is typically more powerful than an analysis of
binary traits because it allows for discernment of differences in
unaffected individuals. In addition, this approach eliminates the
often imprecise process of binning individuals into subjective cat-
egories (such as cases and controls) (De Los Campos et al., 2010;
Stringer et al., 2011).
Furthermore, to keep the treatment uniform across the study
sample, patients undergoing MITOX based therapy were also
removed, leaving 91 patients for the statistical analyses. A detailed
description of this sample population is presented in Table 1.
GENOTYPING
DNA samples from all patients were genotyped for haplotype
tagging (ht) and non-synonymous (ns) SNPs in 35 cytochrome
p450s (CYPs), 23 oxidoreductases (reductases), and two ABC
transporter genes (ABCB1 and ABCG2). The genes were selected
based on their documented or possible role in anthracycline
metabolism (reductases) or efflux (ABC transporter genes). The
CYP genes were also added due to their involvement in redox
cycling, which is also implicated in AIC. The gene sequence used
for SNP selection included 5 kb of gene flanking region upstream
from the start codon and 10kb downstream from the stop codon.
Table 1 | Characteristics of the AML study sample.
Number of patients Females Males Total
43 48 91
Age Average 48.2 48.7 48.4
Range 19–74 20–72 19–74
DAUN cumulative
dose [mg/m2]
Average 293.1 260.4 275.9
Range 50–630 60–540 50–630
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The htSNPs were selected from the HapMap database, release #28
(http://hapmap.ncbi.nlm.nih.gov/) using the Tagger tool and the
following cut-offs: linkage disequilibrium (LD) value (r2) = 0.8
and the minor allele frequency (MAF) cutoff = 1% (De Bakker
et al., 2005). Using these criteria a total of 921 SNPs were selected
to be genotyped. Genotyping was performed using the Sequenom
genotyping system (Sequenom Inc., San Diego, CA). For quality
control, SNPs with call rate of less than 95%, those with minor
allele frequencies less than 1% or not in Hardy-Weinberg equilib-
rium (p > 0.001) were removed from the raw dataset, leaving a
total of 465 SNPs for statistical analysis. All 91 patients had call
rates of at least 90% across the 465 SNPs.
STATISTICAL ANALYSIS
All statistical analyses were performed in the R programming
environment (R-Development-Core-Team, 2011). Genotypes
were coded as 0, 1, and 2 according to the number of copies or
“dosage” of the minor allele. Sporadically missing genotypes were
imputed with the posterior expected dosage of the minor allele,
as estimated by BEAGLE v3.3.1 (Browning and Browning, 2009).
As expected, the distribution of percent drop in LVEF was
highly skewed, with most patients experiencing no or very little
change but a few experiencing drops over 10%. To stabilize vari-
ance and ensure validity of permutation tests, the percent drop
in LVEF was transformed to the logarithmic scale (base 2), after
shifting up values by 1.
Potential confounding variables included age, gender, and
cumulative DAUN dose. An additional source of potential con-
founding is population stratification due to ethnic differences. In
this study ethnicity was measured by the top three principal com-
ponents (PCs) of genetic variation (Price et al., 2006). To capture
ethnicity as completely as possible, additional genotype data for
195 SNPs in 27 oxidative stress response genes (generated for the
patients through a separate study) were added to the genotype
set used to define the PCs. To reduce the number of potential
confounding variables, forward stepwise selection of these vari-
ables in a linear regression model of transformed LVEF drop
was applied, based on predictive ability as measured by Akaike’s
information criterion (Venables and Ripley, 2002). Subsequent
genetic analyses were adjusted for the predictive variables only.
This base model was used to estimate the proportion of vari-
ability in the transformed LVEF drop explained by the potential
confounding variables, so that it could be compared to the pro-
portion of variability explained by SNPs in the set of significant
candidate genes. Candidate genes explaining a proportion of the
variability in LVEF drop that is comparable to variables such as
dose or ethnicity that are suspected to influence cardiotoxicity are
compelling candidates for further investigation.
To test for association of each SNP, a linear model was fit-
ted to the log-transformed LVEF percent drop that adjusts for
dose, the first two genetic PCs, the SNP additive “main effect”
and the SNP’s linear interaction with dose. To summarize the
joint significance of the SNP main effect and interaction, a like-
lihood ratio statistic was calculated. The exact p-value for this
test statistic was approximated by 2000 permutation replicates.
To control the expected proportion of false discoveries among
rejected hypotheses (the false discovery rate or FDR), the nominal
p-values were corrected for multiple testing of SNPs (Benjamini
and Hochberg, 1995). The Manhattan plot of the nominal p-
values was done using the Haploview program (Barrett, 2009).
Testing genes rather than individual SNPs for association with
cardiotoxicity reduces the multiple-testing penalty, enhancing
power in this pilot study. Therefore, each of the 60 candidate
metabolic genes was tested for association with cardiotoxicity
using a global test of its SNP effects and their linear interactions
with dose, as implemented in the Bioconductor package globaltest
(Goeman et al., 2006). This test was chosen because comparative
simulation studies of gene-based tests demonstrate that it is well-
powered under a variety of alternative hypotheses (Pan, 2009).
The global test is motivated by a linearmixedmodel which adjusts
for the fixed effects of confounding variables but specifies ran-
dom effects for SNPs and their interactions with dose. To control
the FDR, the nominal p-values were corrected for multiple testing
of genes (Benjamini and Hochberg, 1995). All p-values for gene-
based associations were obtained from permutation tests based
on 200,000 permutation replicates.
In post-hoc analyses, gene-based associations significant at an
FDR level of 20% were further examined in order to under-
stand which SNPs within a gene were driving the association.
Specifically, the global test statistics were decomposed into the
contributions from each SNP main effect and interaction with
dose in the mixed model, using the inheritance procedure as
implemented in the covariates() function of the globaltest package
(Goeman and Finos, 2012). For SNPs within a gene, a standard
level of 5% was applied to control the family-wise error rate
(FWER) and to minimize the number of false-positive SNPs or
SNP-by-dose interactions incorrectly identified as drivers of the
gene-based association. When decomposing a gene-based asso-
ciation, SNPs were identified as important if they were within
an associated gene (at FDR level 20%) and were also significant
within the gene (at FWER level 5% in the post-hoc analysis), either
through their main effect or through their interaction with dose.
To estimate the proportion of variability in LVEF drop
explained by the candidate metabolic genes, important SNPs
in associated genes were included in an ordinary (fixed effects)
regression model with log-transformed LVEF values as the
response and terms for dose, ethnicity, SNPs and linear interac-
tions of the SNPs with dose. The proportion of variability in the
log-transformed LVEF drop explained by the SNPs in candidate
genes was then estimated from the fittedmodel, without adjusting
for multiple testing.
Pairwise LD between significant SNPs and their haplotype
phase were estimated using the PLINK package (Purcell et al.,
2007).
RESULTS
Initially 286 patients were genotyped in this blinded, retrospec-
tive study. However, subsequent analysis of clinical data identified
variability in assessment of cardiac function. Since the outcome
under investigation was the cardiotoxic effect of anthracycline
treatment and not general cardiac health of the patients, only
patients with LVEF measurements done before and after treat-
ment were included in statistical analyses (114 patients). From
this sample only those patients treated with the anthracycline
DAUN were retained for the statistical analysis (91 patients).
Although this patient selection reduced the sample size, it had the
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benefit of making the sample much more uniform and therefore
less prone to bias from hidden confounding.
To reduce the dimensionality of the data set, we first deter-
mined if the known potential confounding variables (DAUN
dose, patient age, gender, and ethnicity) contributed to the vari-
ance in LVEF drop. Since information on ethnicity was not
available we applied PC analysis using 660 SNPs in 89 genes
to determine the three major axes of genetic variation. These
axes were taken as a summary of the underlying large-scale
population structure and used to correct for population strat-
ification due to ethnic differences. Forward selection of the
potential confounding variables found that anthracycline cumu-
lative dose and the top two genetic PCs are predictive of LVEF
drop. The potential confounding factors, age, and gender, as
well as the third genetic PC were not predictive of LVEF drop
and were therefore excluded from further analyses. Anthracycline
cumulative dose and the top two genetic PCs accounted for an
estimated 13.2% of the variation in the log-transformed LVEF
drop.
Initially we considered 921 SNPs in 60 metabolic and efflux
genes for their effect on % drop in LVEF (Supplemental Table 1).
After eliminating SNPs that did not pass QC filters (see Materials
and Methods), a total of 465 SNPs remained for tests of associ-
ation. Tests for the effect of individual SNPs on drop in LVEF
identified 25 SNPs at a nominal p-value of = 0.05 (Table 2). As
could be expected, given the small number of patients relative to
the number of genetic variants, none of these SNPs survived a
correction for multiple comparisons at FDR level of 20%. This
suggests that if any of the analyzed SNPs has an effect on LVEF
individually, it is probably too small to be detected in the small
sample of patients. However, a Manhattan plot of the nominal
p-values for the single SNP association tests (Figure 1) suggests
that some genes are “enriched” for SNPs with low p-values. This
was especially true for the POR and HSD17B2, where more than
three SNPs in each gene were found to be associated with LVEF
drop at a nominal p-value of less than 0.05. Some of these SNPs,
such as the four SNPs in HSD17B2, were found to be in strong
LD (r2 > 0.8) explaining their concurrent association with LVEF
drop (Table 2). However, others were in weak LD (<0.6) sug-
gesting that their concurrent association with the outcome is due
to factors other than linkage and flags the gene as an interesting
locus.
Another limitation of the Manhattan plot is that the graphic
downplays the gene size, as well as the differences in the number
of SNPs between genes. Therefore, we applied a multi-SNP based
approach in which each of the 60 genes was tested for association
with drop in LVEF using a global test of its SNPs and their linear
interactions with dose (Goeman et al., 2006). This test statis-
tic adjusts for gene size, number of SNPs, and LD between the
SNPs. The unadjusted p-values for the 60 genes are shown in the
quantile-quantile plot (Figure 2A), in which observed p-values
are plotted against p-values expected under the null hypothe-
sis (no genetic association). The FDR-adjusted p-values for the
60 genes are displayed in Figure 2B, with the strongest signal
detected for the POR gene (FDR adjusted p-value = 0.15). After
accounting for the effects of anthracycline dose and ethnicity, the
proportion of variability in the LVEF drop attributable to POR is
estimated to be 11.6% in post-hoc analyses.
Table 2 | Top 25 SNP identified through single SNP tests of
association.
Chr SNP r2 Gene symbol p-value
1 rs837400
0.253
CYP4B1 0.021
1 rs4646495 CYP4B1 0.041
5 rs257970 HSD17B4 0.003
0.912
5 rs2636968 HSD17B4 0.007
7 rs2868177 0.524 POR 0.0025
7 rs13240755
0.948
POR 0.0035
7 rs4732513 POR 0.004
7 rs6953065 0.258 POR 0.0445
10 rs7083869 AKR
0.322
1C4 0.0045
10 rs2151896 AKR1C4 0.045
15 rs2069522
1
CYP1A2 0.004
15 rs2069526 CYP1A2 0.004
15 rs4646427 CYP1A2 0.004
16 rs16956248 HSD17B2 0.023
16 rs13333826 HSD17B2 0.024
16 rs7196087
1
HSD17B2 0.028
16 rs2955159 HSD17B2 0.028
16 rs2966245 0.004 HSD17B2 0.0305
19 rs8112732 0.405 CYP4F11 0.0235
19 rs12610962
1
CYP4F11 0.028
19 rs2072270 CYP4F11 0.0285
19 rs11086012 0.359 CYP4F11 0.051
19 rs1709115 na CYP2F1 0.042
19 rs7255904 na CYP2B6 0.0475
21 rs10483032 na CBR3 0.0045
The p-values have not been corrected for multiple comparisons. r2—squared
correlation coefficient, a measure of linkage disequilibrium (LD). For genes with
more than 2 SNPs the r2 value refers to LD between the SNP and a reference
SNP. r2 > 0.8.
Next, the overall association of LVEF drop with POR was
decomposed into the contributions of each SNP main effect
and its interaction with dose. Three of the 13 SNPs in POR—
rs2868177, rs13240755, and rs4732513—were significant drivers
of the association at 5% FWER level, through their linear
interaction with cumulative DAUN dose. Given that the SNPs
rs13240755 and rs4732513 are in strong LD (r2 = 0.948; D′ =
1.000) only rs13240755 and rs2868177 were included in further
analyses.
To estimate the effect of the two POR SNPs on the risk of AIC
in post-hoc analysis, the patient population was split into high–
risk (at least 15% drop in LVEF) and low–risk (less than 15%
drop in LVEF) groups. The allele frequency distributions at both
loci were significantly different between the two risk groups at 5%
level (Figure 3). The difference in allele frequency was especially
pronounced at rs13240755, where theminor allele (G) was almost
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FIGURE 1 | Results of single-SNP based tests of association with drop in LVEF. A Manhattan plot of log transformed nominal p-values against SNP
chromosomal localization.
twice as frequent in the high risk (0.60) as compared to low risk
group (0.32). For rs2868177, the frequency of the minor allele (G)
was also higher in the high risk group (0.50) than it was in low risk
group (0.35); however the difference was not as large as for the
other SNP. The unadjusted odds ratios (ORs) for rs2868177 and
rs13240755 were estimated to be 1.89 (95%CI: 0.7435–4.819; p =
0.1756) and 3.18 (95%CI: 1.223–8.27; p = 0.01376), respectively.
We caution that these post-hoc estimates of effect sizes, vari-
ability proportions and ORs do not adjust for the multiple testing
and so are descriptive only.
DISCUSSION AND CONCLUSIONS
The use of anthracyclines at optimal efficacy is hampered by their
cumulative dose-dependent adverse side effects, the most serious
of which is the AIC that with time can result in anthracycline
associated cardiomyopathy (AAC) leading to congestive heart fail-
ure. Each anthracycline treatment in addition to killing cancer
cells also kills cardiomyocytes, resulting in AIC (De Angelis et al.,
2010; Sawyer et al., 2010). Due to the limited regenerative capacity
of the heart, cumulative toxicity eventually surpasses a thresh-
old of damage. This triggers a more generic process of ventricular
remodeling which leads to AAC (Sawyer et al., 2010). Therefore,
careful monitoring and reduction of the risk of AIC during treat-
ment will minimize the threat of developing AAC, which can
occur many months or even years later. Biomarkers of the risk of
acute AIC could thus greatly aid in optimizing treatment strate-
gies before treatment begins. The relatively high heritability of
sensitivity of normal cells to anthracyclines indicates that the
inter-patient variability in risk of AIC should at least partially be
explained by common genetic variants (Duan et al., 2007; Peters
et al., 2011).
The exact mechanism of AIC is still unclear; however experi-
mental evidence suggests that accumulation of toxic metabolites
generated during the drug’s metabolism significantly contributes
to the observed cardiotoxicity (Menna et al., 2012; Visscher et al.,
2012). Therefore, we tested SNPs in 60 genes coding for proteins
involved in drug metabolism and efflux (Supplemental Table1)
for association with AIC in a sample of AML patients undergoing
daunorubicin based chemotherapy.
Using the standard single SNP based association test, none
of the analyzed SNPs was found to be significantly associated
with AIC. However, given that the cardiotoxicity due to anthracy-
cline treatment is a complex, polygenic phenotype it is expected
to be weakly associated with single underlying genetic contrib-
utors. Such weak associations are missed by the typical “single-
SNP-at-a-time” analysis due to the high cost of adjustment for
multiple comparisons that are required to control the false dis-
covery rates. In fact, in exploratory studies of multifactorial
phenotypes, correction for multiple comparisons has been crit-
icized as an overly stringent requirement demanding unrealistic
sample sizes (Miaskowski et al., 2013). On the other hand, as
these corrections help to limit the chance of false positive results,
we believe that they should be performed, but with relaxed sig-
nificance thresholds, particularly for complex traits involving a
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FIGURE 2 | Results of gene-based tests of association with drop in
LVEF. (A) Quantile-quantile plot of nominal p-values for the 60 genes
included in analysis—the observed p-values are plotted against p-values
expected under the null hypothesis.(B) Benjamini-Hochberg false-discovery
rates (FDRs) for the 60 analyzed genes. The strongest signal was detected
for the POR gene (FDR adjusted p-value = 0.15).
large number of contributing factors of small effect. Indeed, it has
been shown that a set of SNPs with significance value (P < 0.5)
much below the accepted GWAS threshold (P < 5 × 10−8) was
a better predictor of a complex outcome than a single SNP with
P < 5 × 10−8, despite the fact that many of the SNPs in the set
were probably false positive associations (Purcell et al., 2009).
This suggests that both the number of undetected (weak) variants
as well as their joint effect on the outcome is substantial (Amin
et al., 2009).
To minimize the number of missed associations, we used a
multi-SNP analysis to identify genes associated with the percent
drop in LVEF due to DAUN treatment. This analysis identified
FIGURE 3 | Allele frequency distribution for the two POR SNPs
associated with LVEF drop in high- and low- risk groups. Low risk group
consists of patients with LVEF drop of less than 15% after daunorubicin
therapy. High risk group consists of patients with at least 15% drop in LVEF
after daunorubicin therapy.
P450 oxidoreductase (POR, CPR, CYPOR, P450R) as the gene
most strongly associated with DAUN induced LVEF drop (FDR-
adjusted p-value 15%). The human POR gene has 16 exons and
exons 2–16 code for the 677 amino acid POR protein (NCBI
NP_000932.2). The single copy of the 50 kb POR gene is located
on chromosome 7 (7q11.23). Interestingly, this chromosome was
recently found to harbor a region with significant linkage to
daunorubicin cytotoxicity (Peters et al., 2011). The POR gene
encodes a flavoprotein that transfers electrons from NADPH to
various proteins, including the cytochrome P450 enzymes. The
anthracyclines, as well as other quinone containing compounds,
are converted to semiquinone radical forms by microsomes
through a one electron reduction catalyzed by POR (Bachur et al.,
1979). This bioactivation step stabilizes cross-linking of the drugs
with DNA which is thought to significantly increase their cyto-
toxicity (Kostrzewa-Nowak et al., 2005). At the same time, the
anthracycline bioactivation step generates free radicals that may
further contribute to more widespread anthracycline induced cel-
lular damage (Gille and Nohl, 1997). There is also evidence that
CYP-mediated oxidative metabolism of anthracyclines may con-
tribute to the drug induced cardiotoxicity through generation of
oxidative stress and/or disruption of arachidonic acid metabolism
(Zordoky et al., 2010).
The POR gene is highly polymorphic and a number of POR
genetic variants were shown to have substrate dependent effects
on cytochrome P450 mediated drug metabolism (Gomes et al.,
2009; Miller et al., 2011). The three SNPs found here to drive
the POR association with DAUN induced drop in LVEF are
all located in the intronic region of the gene and thus have
not been assessed for their effect on POR enzyme function.
Interestingly, the SNP rs2868177 has been found to be associ-
ated with inter-individual variability in the levels of warfarin
maintenance dose, suggesting that it may affect POR mediated
metabolism in general (Zhang et al., 2011). The mechanism
underlying this association is beyond the scope of this study.
We can speculate that these intronic SNPs could be tagging
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rare, unidentified mutations that affect the protein sequence.
Alternatively, as has been shown for other risk associated SNPs
in non-coding regions, they could themselves disturb elements
that regulate gene expression or features that modify processing
(Jensen et al., 2009; Ott et al., 2009; Cowper-Sal Lari et al., 2012).
Whichever the case may be, the association of such SNPs with
disease risk is not that unusual. In fact, over 70% of risk asso-
ciated SNPs in the National Genome Research Institute GWAS
do not disturb the protein coding sequence (Abecasis et al.,
2010).
In post-hoc analyses of our study sample, POR is estimated
to account for some 11.6% of the variability in the drop in
LVEF after DAUN treatment, over and above the estimated
13.2% accounted for by cumulative dose and ethnicity. Given
that cumulative anthracycline dose is virtually the only factor
used clinically to predict the risk of developing cardiotoxic-
ity as a result of anthracycline treatment, the contribution that
genetic analyses of POR can make to the assessment of this
risk is worthy of follow up. The SNP rs13240755 was the most
significant driver of the POR association with AIC, with indi-
viduals carrying the G allele having increased risk of cardiotox-
icity (unadjusted OR = 3.18; 95% CI: 1.223–8.27; p = 0.01376).
These point and interval estimates of the OR are expected to be
biased away from one as a result of the multiple genes queried
(Ioannidis, 2008). Thus, validation of these results in an inde-
pendent study is required. Once validated, the POR alleles can
be included in a panel with other genetic and non-genetic risk
factors, to predict AIC. Given that anthracyclines are used in
the treatment of a wide variety of cancers including HER2 pos-
itive breast cancer, hematological malignancies, soft tissue sar-
comas, and many types of carcinomas (http://www.bccancer.bc.
ca/HPI/DrugDatabase/DrugIndexPro/Doxorubicin.htm), such a
panel of risk factors should improve the clinical outcome of
a substantial number of cancer patients. Additionally, this per-
sonalized approach to cancer treatment should reduce the cost
of health care by eliminating inappropriate treatments (that is,
those cases in which the patient derives no therapeutic bene-
fit) and reducing number of conditions caused by adverse drug
reactions.
A limitation of this study is the small sample size. However,
unfortunate, this candidly is a reflection of the challenges of
pharmacogenomic studies in cancer patient populations under-
going heterogeneous treatments (Wheeler et al., 2012; McLeod,
2013). Even in the case of more common cancers, objective char-
acterization of drug response phenotype is faced with lack of
uniform treatments and the tumor molecular heterogeneity. The
need for relatively homogeneous patient populations for accu-
rate assessment of the genetic effect on drug response will result
in a decrease of the study population size. For very common
forms of cancer, relatively large, uniform populations can be
potentially recruited through a prospective study; however, for
less common cancers such approaches would take many years
to complete and are impossible for any single research group.
The impracticality of randomized, controlled, prospective tri-
als for clinical implementation and a need for a more efficient
approach has been recently discussed in more detail elsewhere
(Hattersley and McCarthy, 2005; Wheeler et al., 2012; McLeod,
2013; Miaskowski et al., 2013). We believe that publication of
preliminary discoveries, even of marginal statistical significance,
can facilitate the translation of potential biomarkers into clinics.
Such preliminary candidates can be included by other research
groups in validation studies. Furthermore, there may be simi-
lar findings discovered at an independent research center that
are not being published because of similar strict requirements
but in fact represent an independent validation sample, as has
been the case with a SNP associated with methotrexate clear-
ance (Trevino et al., 2009; Lopez-Lopez et al., 2011). Although
the POR SNP association with DAUN induced cardiotoxicity
has not been reported by other research groups, the SNP has
been found to be associated with levels of warfarin maintenance
dose (Zhang et al., 2011), and thus may represent a general
marker of drug clearance. This speculation is supported by the
essential role of POR for the function of the cytochrome P450
system.
Lastly, our study provides additional support for the recent
observations which suggest that identification of a comprehen-
sive list of markers for complex traits requires more than a
simple increase in the size of study sample, especially since
the required sample size for classic genetic association stud-
ies of multifactorial phenotypes is estimated to have unrealistic
magnitude (Purcell et al., 2009; Yang et al., 2010; Ober and
Vercelli, 2011; Han et al., 2012; Urbach et al., 2012; Wheeler
et al., 2012). We strongly support the need for modification of
the experimental approach and application of statistical models
that take into account the multifactorial (genetic and environ-
mental) character of such traits, including interaction between
them. As the cost of generating data plummets there is a con-
tinually increasing need for more sophisticated approaches to
genome wide analyses. The future of personalized medicine now
depends on careful attention to study design, and the devel-
opment and application of more powerful analytic approaches
to the resulting data (Urbach et al., 2012; Wheeler et al.,
2012).
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